TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 16764746

Group type: EXPERIMENTAL
Intervention: High-dose cyclophosphamide/thiotepa/carboplatin
Number of subjects: 29

Group type: EXPERIMENTAL
Intervention: Conventional-dose cyclophosphamide/epirubicin/5-fluorouracil
Number of subjects: 29

Group type: COMPARATOR
Intervention: Control group (not treated with chemotherapy)
Number of subjects: 29
Study: 12763216

Group type: EXPERIMENTAL
Intervention: Temozolomide 200 mg/m(2)/day, administered orally for 5 consecutive days of a 28-day cycle, continued for up to six cycles.
Number of subjects: 25

Group type: EXPERIMENTAL
Intervention: Temozolomide (patients with BM)
Number of subjects: 25

Group type: EXPERIMENTAL
Intervention: Temozolomide (patients without BM)
Number of subjects: 25
Study: 11141365

Group type: EXPERIMENTAL
Intervention: Ibuprofen suspension (7 mg/kg)
Number of subjects: 103

Group type: COMPARATOR
Intervention: Effervescent granules (200 mg for 25-40 kg; 400 mg for 35-40 kg; 400 mg for >40 kg)
Number of subjects: 103
Study: 9296729

Group type: EXPERIMENTAL
Intervention: Outpatient cardiological rehabilitation programme
Number of subjects: 155

Group type: COMPARATOR
Intervention: Non-treatment group
Number of subjects: 155
Study: 8409079

Group type: EXPERIMENTAL
Intervention: Antioxidant-rich foods (group A)
Number of subjects: 406

Group type: COMPARATOR
Intervention: Control group (group B)
Number of subjects: 406
Study: 3012991

Group type: EXPERIMENTAL
Intervention: 30 g soy polysaccharide
Number of subjects: 16

Group type: EXPERIMENTAL
Intervention: 60 g soy polysaccharide
Number of subjects: 16

Group type: COMPARATOR
Intervention: 0 g soy polysaccharide
Number of subjects: 16

Group type: EXPERIMENTAL
Intervention: 30 g (heat processed) soy polysaccharide
Number of subjects: 16
Study: 30945092

Group type: EXPERIMENTAL
Intervention: Special education services under the Autism classification
Number of subjects: 89

Group type: EXPERIMENTAL
Intervention: Partial-inclusion settings
Number of subjects: 89

Group type: EXPERIMENTAL
Intervention: Speech therapy
Number of subjects: 89

Group type: EXPERIMENTAL
Intervention: Occupational therapy
Number of subjects: 89

Group type: EXPERIMENTAL
Intervention: Behavior plans
Number of subjects: 89

Group type: EXPERIMENTAL
Intervention: Social skills instruction
Number of subjects: 89
Study: 30344873

Group type: EXPERIMENTAL
Intervention: Kangaroo Mother Care (KMC) for 1 hour daily over 7 days
Number of subjects: 100

Group type: COMPARATOR
Intervention: Routine care in the incubator
Number of subjects: 100
Study: 26919044

Group type: EXPERIMENTAL
Intervention: Motivational engagement (M+)
Number of subjects: 68

Group type: COMPARATOR
Intervention: Standard care (M-)
Number of subjects: 68
Study: 25422824

Group type: EXPERIMENTAL
Intervention: 6.6‐mm long implants
Number of subjects: 60

Group type: COMPARATOR
Intervention: 9.6 mm or longer implants
Number of subjects: 60
Study: 22634246

Group type: EXPERIMENTAL
Intervention: Cigarettes with different loadings of synthetic and natural l-menthol (1 and 4mg ISO tar yields)
Number of subjects: 200

Group type: COMPARATOR
Intervention: Cigarettes with no menthol
Number of subjects: 200
Study: 19954383

Group type: EXPERIMENTAL
Intervention: Intermittent preventive treatment with sulfadoxine‐pyrimethamine (IPTp-SP) in HIV-positive mothers
Number of subjects: 302

Group type: COMPARATOR
Intervention: Placebo in HIV-positive mothers
Number of subjects: 302

Group type: EXPERIMENTAL
Intervention: Intermittent preventive treatment with sulfadoxine‐pyrimethamine (IPTp-SP) in HIV-negative mothers
Number of subjects: 302

Group type: COMPARATOR
Intervention: Placebo in HIV-negative mothers
Number of subjects: 302

Group type: EXPERIMENTAL
Intervention: Intermittent preventive treatment with sulfadoxine‐pyrimethamine (IPTp-SP)
Number of subjects: 302
Study: 17563237

Group type: EXPERIMENTAL
Intervention: ABQ method for diagnosing vertebral fractures
Number of subjects: 732

Group type: EXPERIMENTAL
Intervention: SQ method for diagnosing vertebral fractures
Number of subjects: 732

Group type: EXPERIMENTAL
Intervention: QM-triage method for diagnosing vertebral fractures
Number of subjects: 732

Group type: EXPERIMENTAL
Intervention: ABQ method for diagnosing short vertebral height
Number of subjects: 732

Group type: EXPERIMENTAL
Intervention: Comparison of BMD in men with VF vs. without VF
Number of subjects: 732

Group type: EXPERIMENTAL
Intervention: Comparison of BMD in men with SVH vs. normal vertebrae
Number of subjects: 732

Group type: EXPERIMENTAL
Intervention: Analysis of BMD in men with VF identified by all three methods
Number of subjects: 732

Group type: EXPERIMENTAL
Intervention: Analysis of BMD in men identified by a single method
Number of subjects: 732
Study: 15711503

Group type: EXPERIMENTAL
Intervention: 80% oxygen and 20% nitrogen during anesthesia and 80% oxygen in recovery
Number of subjects: 38

Group type: COMPARATOR
Intervention: 70% nitrous oxide and 30% oxygen during anesthesia, followed by 30% oxygen in recovery
Number of subjects: 38
Study: 12502651

Group type: EXPERIMENTAL
Intervention: Pramlintide (30 microg t.i.d. for 4 weeks)
Number of subjects: 18
Study: 10098585

Group type: EXPERIMENTAL
Intervention: Epidural + general anesthesia + Aprotinin
Number of subjects: 60

Group type: COMPARATOR
Intervention: Epidural + general anesthesia + placebo
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: General anesthesia + Aprotinin
Number of subjects: 60

Group type: COMPARATOR
Intervention: General anesthesia + placebo
Number of subjects: 60
Study: 8678393

Group type: EXPERIMENTAL
Intervention: Interferon therapy for chronic hepatitis C infection (mean duration 19.5 months)
Number of subjects: 35

Group type: COMPARATOR
Intervention: Untreated control group (mean follow-up 28 months)
Number of subjects: 35
Study: 1880224

Group type: EXPERIMENTAL
Intervention: Alprazolam 0.5 mg
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: Alprazolam 2 mg
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: Alprazolam (general)
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: Alpha-hydroxyalprazolam
Number of subjects: 24
Study: 7105818

Group type: EXPERIMENTAL
Intervention: Cefaclor, 150 mg 3-times daily
Number of subjects: 87

Group type: COMPARATOR
Intervention: Amoxycillin, 150 mg 3-times daily
Number of subjects: 87

Group type: EXPERIMENTAL
Intervention: Cefaclor (hospital-acquired infection)
Number of subjects: 87

Group type: COMPARATOR
Intervention: Amoxycillin (hospital-acquired infection)
Number of subjects: 87
Study: 31233662

Group type: EXPERIMENTAL
Intervention: Pain diary
Number of subjects: 389

Group type: COMPARATOR
Intervention: Comfort diary
Number of subjects: 389
Study: 28827788

Group type: EXPERIMENTAL
Intervention: Vitamin D supplementation (VD group, n=29)
Number of subjects: 54

Group type: COMPARATOR
Intervention: Placebo (placebo group, n=29)
Number of subjects: 54
Study: 28586586

Group type: EXPERIMENTAL
Intervention: Transpatellar tendon approach
Number of subjects: 60

Group type: COMPARATOR
Intervention: Medial parapatellar tendon approach
Number of subjects: 60
Study: 24589242

Group type: EXPERIMENTAL
Intervention: Bromelain (4 × 250 mg)
Number of subjects: 45

Group type: EXPERIMENTAL
Intervention: Diclofenac sodium (4 × 25 mg)
Number of subjects: 45

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 45
Study: 22070512

Group type: EXPERIMENTAL
Intervention: Ilaprazole (10 mg/d)
Number of subjects: 494

Group type: COMPARATOR
Intervention: Omeprazole (20 mg/d)
Number of subjects: 494
Study: 20667792

Group type: EXPERIMENTAL
Intervention: Omega-3 fatty acids
Number of subjects: 19

Group type: EXPERIMENTAL
Intervention: Other time-dependent measures of HRV (SDNN, SDANN)
Number of subjects: 19
Study: 17604453

Group type: EXPERIMENTAL
Intervention: Phenotype frequencies of ten autosomal minor H antigens
Number of subjects: 2685
Study: 16097050

Group type: EXPERIMENTAL
Intervention: High-volume CVVH
Number of subjects: 37

Group type: COMPARATOR
Intervention: Low-volume CVVH
Number of subjects: 37

Group type: EXPERIMENTAL
Intervention: Early CVVH
Number of subjects: 37

Group type: COMPARATOR
Intervention: Late CVVH
Number of subjects: 37

Group type: EXPERIMENTAL
Intervention: Survival patients
Number of subjects: 37
Study: 12200812

Group type: EXPERIMENTAL
Intervention: High doses of recombinant human EPO (rHuEPO) in groups A and C1
Number of subjects: 47

Group type: EXPERIMENTAL
Intervention: Vitamin E-modified membranes (CL-Es) in group C
Number of subjects: 47

Group type: COMPARATOR
Intervention: Low doses of rHuEPO in groups B and C2
Number of subjects: 47
Study: 10029961

Group type: EXPERIMENTAL
Intervention: 10% povidone iodine
Number of subjects: 31

Group type: COMPARATOR
Intervention: Placebo (commercial instant tea and deionized water)
Number of subjects: 31
Study: 8559499

Group type: EXPERIMENTAL
Intervention: Fish oil supplementation (6 g/day) for 12 weeks
Number of subjects: 12

Group type: COMPARATOR
Intervention: Cyclosporin A (CsA) (3 mg/kg)
Number of subjects: 12

Group type: COMPARATOR
Intervention: Control study without CsA intake
Number of subjects: 12
Study: 1988894

Group type: EXPERIMENTAL
Intervention: Bladder training
Number of subjects: 108
Study: 6182469

Group type: EXPERIMENTAL
Intervention: Starch-blocker tablets
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 31587103

Group type: EXPERIMENTAL
Intervention: Bioabsorbable polymer-coated everolimus-eluting stents (BP-EES)
Number of subjects: 13

Group type: COMPARATOR
Intervention: Bioresorbable vascular scaffolds (BVS)
Number of subjects: 13
Study: 31646767

Group type: EXPERIMENTAL
Intervention: Single 10 mg/kg intravenous dose of methylprednisolone
Number of subjects: 64

Group type: EXPERIMENTAL
Intervention: Higher (30 mg/kg) or more frequent (twice) dosing of methylprednisolone
Number of subjects: 64

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 64
Study: 27716660

Group type: EXPERIMENTAL
Intervention: Escitalopram
Number of subjects: 84

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 84
Study: 26394225

Group type: EXPERIMENTAL
Intervention: Speed Endurance Production (SEP) training
Number of subjects: 13

Group type: EXPERIMENTAL
Intervention: Speed Endurance Maintenance (SEM) training
Number of subjects: 13
Study: 22392970

Group type: EXPERIMENTAL
Intervention: Essential oil of ginger
Number of subjects: 301

Group type: EXPERIMENTAL
Intervention: Blend of essential oils (ginger, spearmint, peppermint, cardamom)
Number of subjects: 301

Group type: EXPERIMENTAL
Intervention: Isopropyl alcohol
Number of subjects: 301

Group type: COMPARATOR
Intervention: Saline (placebo)
Number of subjects: 301
Study: 21334898

Group type: EXPERIMENTAL
Intervention: Decreased ankle pushoff instructions
Number of subjects: 24

Group type: COMPARATOR
Intervention: Increased ankle pushoff instructions
Number of subjects: 24
Study: 19135958

Group type: EXPERIMENTAL
Intervention: Ignatia homeopathic 30C
Number of subjects: 30

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 30
Study: 17569404

Group type: EXPERIMENTAL
Intervention: Clobetasol propionate shampoo 0.05% for 5 minutes
Number of subjects: 55

Group type: EXPERIMENTAL
Intervention: Clobetasol propionate shampoo 0.05% for 10 minutes
Number of subjects: 55

Group type: COMPARATOR
Intervention: Clobetasol propionate vehicle for 10 minutes
Number of subjects: 55

Group type: EXPERIMENTAL
Intervention: Ketoconazole foaming gel 2% for 5 minutes
Number of subjects: 55
Study: 15186234

Group type: EXPERIMENTAL
Intervention: Fiber-optic broad-band UVB comb, treated three times a week for up to 12 weeks
Number of subjects: 14

Group type: COMPARATOR
Intervention: Control area (minimum 50-cm² scalp area)
Number of subjects: 14
Study: 11156490

Group type: EXPERIMENTAL
Intervention: Functional index for hand osteoarthritis (FIHOA)
Number of subjects: 261

Group type: EXPERIMENTAL
Intervention: Pain on visual analog scale (VAS)
Number of subjects: 261

Group type: EXPERIMENTAL
Intervention: Morning stiffness duration
Number of subjects: 261

Group type: EXPERIMENTAL
Intervention: Grip strength
Number of subjects: 261
Study: 9298686

Group type: EXPERIMENTAL
Intervention: Vitamin E 100 IU
Number of subjects: 83

Group type: COMPARATOR
Intervention: Control (placebo)
Number of subjects: 83
Study: 1622175

Group type: EXPERIMENTAL
Intervention: Fleroxacin (400 mg) administered orally and intravenously
Number of subjects: 12

Group type: COMPARATOR
Intervention: Healthy controls (no specific intervention mentioned)
Number of subjects: 12
Study: 4083568

Group type: EXPERIMENTAL
Intervention: CL 115,347 (1000 mcg)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: CL 115,347 (500 mcg and 1500 mcg)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 31250668

Group type: EXPERIMENTAL
Intervention: DOT‐HTN
Number of subjects: 20

Group type: COMPARATOR
Intervention: Standard ABPM
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: VAS assessment
Number of subjects: 20
Study: 29106448

Group type: EXPERIMENTAL
Intervention: LMWH enoxaparin (1 mg/kg)
Number of subjects: 390

Group type: COMPARATOR
Intervention: Control
Number of subjects: 390
Study: 26216477

Group type: COMPARATOR
Intervention: 0 g GAA/kg diet
Number of subjects: 520

Group type: EXPERIMENTAL
Intervention: 0.6 g GAA/kg diet
Number of subjects: 520

Group type: EXPERIMENTAL
Intervention: 1.2 g GAA/kg diet
Number of subjects: 520

Group type: EXPERIMENTAL
Intervention: 1.8 g GAA/kg diet
Number of subjects: 520

Group type: EXPERIMENTAL
Intervention: 1.2 g GAA/kg diet with 0 g ARG/kg diet
Number of subjects: 520

Group type: EXPERIMENTAL
Intervention: 1.2 g GAA/kg diet with 3 g ARG/kg diet
Number of subjects: 520

Group type: EXPERIMENTAL
Intervention: 1.2 g GAA/kg diet with 6 g ARG/kg diet
Number of subjects: 520

Group type: EXPERIMENTAL
Intervention: 1.2 g GAA/kg diet with 9 g ARG/kg diet
Number of subjects: 520
Study: 25209897

Group type: EXPERIMENTAL
Intervention: Model OA consultation (MOAC) implementing NICE OA guidelines
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Model OA consultation (MOAC)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Training for GPs and practice nurses
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control practices
Number of subjects: 0
Study: 22414507

Group type: EXPERIMENTAL
Intervention: Glazed zirconia
Number of subjects: 40

Group type: COMPARATOR
Intervention: Ground, finished, and polished zirconia
Number of subjects: 40
Study: 20576829

Group type: EXPERIMENTAL
Intervention: Home hemodialysis training
Number of subjects: 0
Study: 17150221

Group type: EXPERIMENTAL
Intervention: Tadalafil (20mg every other day)
Number of subjects: 36

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 36
Study: 15871847

Group type: EXPERIMENTAL
Intervention: Sibutramine (15 mg o.i.d. combined with diet)
Number of subjects: 20

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Sibutramine
Number of subjects: 20
Study: 12970285

Group type: EXPERIMENTAL
Intervention: r-human chorionic gonadotropin (r-hCG) 250 microg (n = 11)
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: recombinant luteinizing hormone (r-LH) 1 mg (n = 13)
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: GnRH agonist (triptorelin; 0.2 mg) (n = 15)
Number of subjects: 40
Study: 10757272

Group type: EXPERIMENTAL
Intervention: On-demand follow-up by a specialist nurse (NG)
Number of subjects: 400

Group type: COMPARATOR
Intervention: Traditional follow-up by a urologist (UG)
Number of subjects: 400
Study: 8854470

Group type: EXPERIMENTAL
Intervention: Physiotherapy with flutter VRP1 device
Number of subjects: 20

Group type: COMPARATOR
Intervention: Sham therapy (control group)
Number of subjects: 20
Study: 1524143

Group type: EXPERIMENTAL
Intervention: Permethrin-treated bed nets
Number of subjects: 261

Group type: COMPARATOR
Intervention: Untreated nets
Number of subjects: 261
Study: 427002

Group type: EXPERIMENTAL
Intervention: 5 mg i.v. pindolol
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Oral pindolol (5, 10, and 20 mg)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Not applicable
Number of subjects: 0
Study: 31655883

Group type: EXPERIMENTAL
Intervention: Extracorporeal shock wave therapy (ESWT)
Number of subjects: 55

Group type: COMPARATOR
Intervention: Local corticosteroid injection (LCI)
Number of subjects: 55
Study: 30116006

Group type: EXPERIMENTAL
Intervention: 8-mg ondansetron
Number of subjects: 53

Group type: EXPERIMENTAL
Intervention: 16-mg ondansetron
Number of subjects: 53

Group type: EXPERIMENTAL
Intervention: 24-mg ondansetron
Number of subjects: 53

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 53
Study: 27471856

Group type: EXPERIMENTAL
Intervention: Neonatal vitamin A supplementation (single dose of 50,000 international units within 48-72 hours after birth)
Number of subjects: 11028

Group type: COMPARATOR
Intervention: Placebo (identical capsules)
Number of subjects: 11028

Group type: EXPERIMENTAL
Intervention: Neonatal vitamin A supplementation
Number of subjects: 11028

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 11028
Study: 25552328

Group type: EXPERIMENTAL
Intervention: 2:1 mixture of 9 mg/ml propofol and 4.5 mg/ml ketamine (Group 1)
Number of subjects: 80

Group type: COMPARATOR
Intervention: 4:1 mixture of 9 mg/ml propofol and 2.25 mg/ml ketamine (Group 2)
Number of subjects: 80
Study: 23995982

Group type: EXPERIMENTAL
Intervention: Isolated patients
Number of subjects: 170

Group type: COMPARATOR
Intervention: Non-isolated patients
Number of subjects: 170
Study: 21351838

Group type: EXPERIMENTAL
Intervention: Controlled-release vaginal dinoprostone pessary
Number of subjects: 52

Group type: COMPARATOR
Intervention: Vaginal dinoprostone gel
Number of subjects: 52
Study: 19135574

Group type: EXPERIMENTAL
Intervention: Carra/LNG gel (0.75 mg in 4 mL) with sexual intercourse after 2-4 hours
Number of subjects: 12

Group type: COMPARATOR
Intervention: Carra/LNG gel (0.75 mg in 4 mL) with abstinence
Number of subjects: 12
Study: 17339186

Group type: EXPERIMENTAL
Intervention: UFH 180 UI/Kg x 2/day s.c.
Number of subjects: 43

Group type: EXPERIMENTAL
Intervention: Enoxaparin 100 UI/Kg x 2/day s.c.
Number of subjects: 43
Study: 16321141

Group type: EXPERIMENTAL
Intervention: 500 ml of water
Number of subjects: 9

Group type: COMPARATOR
Intervention: 50 ml of water (control)
Number of subjects: 9
Study: 14616202

Group type: EXPERIMENTAL
Intervention: Iodixanol (Visipaque 270 mg I/ml)
Number of subjects: 352

Group type: COMPARATOR
Intervention: Iomeprol (Iomeron 300 mg I/ml)
Number of subjects: 352
Study: 10363854

Group type: EXPERIMENTAL
Intervention: Oral antibiotics
Number of subjects: 73

Group type: COMPARATOR
Intervention: IV antibiotics
Number of subjects: 73

Group type: EXPERIMENTAL
Intervention: Outpatient care
Number of subjects: 73

Group type: COMPARATOR
Intervention: Inpatient treatment
Number of subjects: 73
Study: 8614310

Group type: EXPERIMENTAL
Intervention: Tocotrienols (Palm Vitee)
Number of subjects: 50

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 50
Study: 2269032

Group type: EXPERIMENTAL
Intervention: Colloidal bismuth subcitrate (CBS) 120 mg four times a day
Number of subjects: 80

Group type: COMPARATOR
Intervention: Ranitidine 150 mg twice daily
Number of subjects: 80

Group type: EXPERIMENTAL
Intervention: Colloidal bismuth subcitrate (CBS)
Number of subjects: 80

Group type: COMPARATOR
Intervention: Ranitidine
Number of subjects: 80
Study: 6969194

Group type: EXPERIMENTAL
Intervention: tiaprofenic acid 200 mg t.d.s.
Number of subjects: 100

Group type: COMPARATOR
Intervention: aspirin 600 mg t.d.s.
Number of subjects: 100
Study: 29800130

Group type: EXPERIMENTAL
Intervention: Inhalation of nitric oxide (iNO) at 80 parts-per-million for 4 hours after percutaneous revascularization
Number of subjects: 250

Group type: COMPARATOR
Intervention: Control group inhaling oxygen without nitric oxide (CON)
Number of subjects: 250

Group type: EXPERIMENTAL
Intervention: Inhalation of nitric oxide (iNO)
Number of subjects: 250
Study: 27062174

Group type: EXPERIMENTAL
Intervention: Meperidine 0.4mg/kg
Number of subjects: 160

Group type: COMPARATOR
Intervention: 0.9% saline solution (placebo)
Number of subjects: 160
Study: 24517173

Group type: COMPARATOR
Intervention: Personalized oxycodone dosing based on CYP2D6 phenotype testing and clinical pharmacokinetics.
Number of subjects: 15

Group type: COMPARATOR
Intervention: CYP2D6 phenotype testing and pharmacokinetics analysis.
Number of subjects: 15
Study: 23145765

Group type: EXPERIMENTAL
Intervention: Acupuncture treatment together with Western standard treatment for 2 weeks plus secondary prevention treatment for 22 weeks
Number of subjects: 328

Group type: COMPARATOR
Intervention: Western standard treatment for 2 weeks and secondary prevention treatment for 22 weeks
Number of subjects: 328
Study: 20724673

Group type: EXPERIMENTAL
Intervention: Lay health worker home visit
Number of subjects: 234

Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 234
Study: 17976537

Group type: EXPERIMENTAL
Intervention: Transdermal nicotine
Number of subjects: 30

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 30
Study: 15772469

Group type: EXPERIMENTAL
Intervention: Active Insuflow device (warmed and humidified intraperitoneal gases)
Number of subjects: 50

Group type: COMPARATOR
Intervention: Control group (room temperature insufflation gases)
Number of subjects: 50
Study: 12441803

Group type: EXPERIMENTAL
Intervention: Therapeutic drug monitoring (TDM) arm
Number of subjects: 183

Group type: COMPARATOR
Intervention: Control arm
Number of subjects: 183

Group type: EXPERIMENTAL
Intervention: TDM arm
Number of subjects: 183
Study: 10625114

Group type: EXPERIMENTAL
Intervention: Neuroleptics combined with vitamin E (600 IU/day) for two weeks
Number of subjects: 39

Group type: COMPARATOR
Intervention: Neuroleptics alone
Number of subjects: 39
Study: 8749696

Group type: EXPERIMENTAL
Intervention: Urinary beta 2‐microglobulin excretion > 500 ng/min
Number of subjects: 30

Group type: COMPARATOR
Intervention: Urinary beta 2‐microglobulin excretion < or = 500 ng/min
Number of subjects: 30
Study: 2290769

Group type: EXPERIMENTAL
Intervention: Written health education
Number of subjects: 100

Group type: COMPARATOR
Intervention: Control group (no written health education)
Number of subjects: 100
Study: 6793053

Group type: EXPERIMENTAL
Intervention: Etomidate and fentanyl
Number of subjects: 200

Group type: COMPARATOR
Intervention: Halothane or morphine plus nitrous oxide
Number of subjects: 200
Study: 30629458

Group type: EXPERIMENTAL
Intervention: n-3 fatty acid supplementation (5 g/d)
Number of subjects: 20

Group type: COMPARATOR
Intervention: Control (sunflower oil, isoenergetic quantity)
Number of subjects: 20
Study: 28575932

Group type: EXPERIMENTAL
Intervention: Firewood/Kerosene stove users (Group A)
Number of subjects: 96

Group type: EXPERIMENTAL
Intervention: Bioethanol stove users (Group B)
Number of subjects: 96

Group type: COMPARATOR
Intervention: Chicago women (Control Group C)
Number of subjects: 96
Study: 25529189

Group type: EXPERIMENTAL
Intervention: Aortoiliac stent (AIS) placement
Number of subjects: 68

Group type: COMPARATOR
Intervention: Surgical treatment
Number of subjects: 68
Study: 23657892

Group type: EXPERIMENTAL
Intervention: Radiofrequency (RF) ablation
Number of subjects: 49
Study: 21874390

Group type: EXPERIMENTAL
Intervention: Surgical navigation group (50 TKAs)
Number of subjects: 97

Group type: COMPARATOR
Intervention: Standard technique group (50 TKAs)
Number of subjects: 97